Abstract
Insulin analogs are gradually becoming the standard for further treatment of diabetes in Western Europe and the United States. Their development was stimulated by the imperfect pharmacokinetics and pharmacodynamics of human insulins.
The main requirements to be met by analog, actually meet. Insulin analogues have a demonstrably lower intra-individual variability in effect, which in practice means that their effect may be better predicted and therefore can be used to safely titrate efficacy to glycemic values that are closer to that of a healthy person.
Short-acting analogs have been shown to have a faster onset of action and a shorter duration of action, so that they do indeed replicate the physiological secretion curve in another postprandial manner.